Details

Autor(en) / Beteiligte

• Cattaneo, Chiara
• Marchesi, Francesco
• Terrenato, Irene
• Bonuomo, Valentina
• Fracchiolla, Nicola Stefano
• Delia, Mario
• Criscuolo, Marianna
• Candoni, Anna
• Prezioso, Lucia
• Facchinelli, Davide
• Pasciolla, Crescenza
• Del Principe, Maria Ilaria
• Dargenio, Michelina
• Buquicchio, Caterina
• Mitra, Maria Enza
• Farina, Francesca
• Borlenghi, Erika
• Nadali, Gianpaolo
• Gagliardi, Vito Pier
• Fianchi, Luana
• Sciumè, Mariarita
• Menna, Pierantonio
• Busca, Alessandro
• Rossi, Giuseppe
• Pagano, Livio

Titel

High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study

Ist Teil von

• Journal of fungi (Basel), 2022-05, Vol.8 (6), p.583

Ort / Verlag

Basel: MDPI AG

Erscheinungsjahr

2022

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• The potential drug-drug interactions of midostaurin may impact the choice of antifungal (AF) prophylaxis in FLT3-positive acute myeloid leukemia (AML) patients. To evaluate the incidence of invasive fungal diseases (IFD) during the treatment of FLT3-mutated AML patients and to correlate it to the different AF prophylaxis strategies, we planned a multicenter observational study involving 15 SEIFEM centers. One hundred fourteen patients treated with chemotherapy + midostaurin as induction/reinduction, consolidation or both were enrolled. During induction, the incidence of probable/proven and possible IFD was 10.5% and 9.7%, respectively; no statistically significant difference was observed according to the different AF strategy adopted. The median duration of neutropenia was similar in patients with or without IFD. Proven/probable and possible IFD incidence was 2.4% and 1.8%, respectively, during consolidation. Age was the only risk factor for IFD (OR, 95% CI, 1.10 [1.03–1.19]) and complete remission achievement after first induction the only one for survival (OR, 95% CI, 5.12 [1.93–13.60]). The rate of midostaurin discontinuation was similar across different AF strategies. The IFD attributable mortality during induction was 8.3%. In conclusion, the 20.2% overall incidence of IFD occurring in FLT3-mutated AML during induction with chemotherapy + midostaurin, regardless of AF strategy type, was noteworthy, and merits further study, particularly in elderly patients.